Cargando…

Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer

Cancer biology is influenced by the tumor microenvironment that impacts on disease prognosis and therapeutic intervention. The inter-relationship of tumor infiltrating lymphocytes, immune response regulators, and a glycolytic tumor environment was evaluated in a cohort of 183 largely consecutive pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Thomas A., Vail, Paris J., Ruiz, Amanda, Mollaee, Mehri, McCue, Peter A., Knudsen, Erik S., Witkiewicz, Agnieszka K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963501/
https://www.ncbi.nlm.nih.gov/pubmed/28984302
http://dx.doi.org/10.1038/modpathol.2017.126
_version_ 1783325044906131456
author Adams, Thomas A.
Vail, Paris J.
Ruiz, Amanda
Mollaee, Mehri
McCue, Peter A.
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
author_facet Adams, Thomas A.
Vail, Paris J.
Ruiz, Amanda
Mollaee, Mehri
McCue, Peter A.
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
author_sort Adams, Thomas A.
collection PubMed
description Cancer biology is influenced by the tumor microenvironment that impacts on disease prognosis and therapeutic intervention. The inter-relationship of tumor infiltrating lymphocytes, immune response regulators, and a glycolytic tumor environment was evaluated in a cohort of 183 largely consecutive patients with triple negative breast cancer diagnosis. High levels of tumor infiltrating lymphocytes were associated with improved survival of triple negative breast cancer cases. However, elevated levels of PD-L1, CD163, and FOXP3 were individually associated with significantly decreased overall survival. These three determinants were significantly correlated, and could serve to differentiate the prognostic significance of tumor infiltrating lymphocytes. Interestingly, a glycolytic tumor environment, as determined by the expression of MCT4 in the tumor stroma, was associated with the immune evasive environment and poor prognosis. Clustering of all markers defined four distinct triple negative breast cancer subtypes that harbored prognostic significance in multi-variate analysis. Immune and metabolic markers stratify triple negative breast cancer into subtypes that have prognostic significance and implications for therapies targeting immune checkpoints and tumor metabolism.
format Online
Article
Text
id pubmed-5963501
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-59635012018-05-23 Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer Adams, Thomas A. Vail, Paris J. Ruiz, Amanda Mollaee, Mehri McCue, Peter A. Knudsen, Erik S. Witkiewicz, Agnieszka K. Mod Pathol Article Cancer biology is influenced by the tumor microenvironment that impacts on disease prognosis and therapeutic intervention. The inter-relationship of tumor infiltrating lymphocytes, immune response regulators, and a glycolytic tumor environment was evaluated in a cohort of 183 largely consecutive patients with triple negative breast cancer diagnosis. High levels of tumor infiltrating lymphocytes were associated with improved survival of triple negative breast cancer cases. However, elevated levels of PD-L1, CD163, and FOXP3 were individually associated with significantly decreased overall survival. These three determinants were significantly correlated, and could serve to differentiate the prognostic significance of tumor infiltrating lymphocytes. Interestingly, a glycolytic tumor environment, as determined by the expression of MCT4 in the tumor stroma, was associated with the immune evasive environment and poor prognosis. Clustering of all markers defined four distinct triple negative breast cancer subtypes that harbored prognostic significance in multi-variate analysis. Immune and metabolic markers stratify triple negative breast cancer into subtypes that have prognostic significance and implications for therapies targeting immune checkpoints and tumor metabolism. 2017-10-06 2018-02 /pmc/articles/PMC5963501/ /pubmed/28984302 http://dx.doi.org/10.1038/modpathol.2017.126 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Adams, Thomas A.
Vail, Paris J.
Ruiz, Amanda
Mollaee, Mehri
McCue, Peter A.
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title_full Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title_fullStr Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title_full_unstemmed Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title_short Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
title_sort composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963501/
https://www.ncbi.nlm.nih.gov/pubmed/28984302
http://dx.doi.org/10.1038/modpathol.2017.126
work_keys_str_mv AT adamsthomasa compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT vailparisj compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT ruizamanda compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT mollaeemehri compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT mccuepetera compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT knudseneriks compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer
AT witkiewiczagnieszkak compositeanalysisofimmunologicalandmetabolicmarkersdefinesnovelsubtypesoftriplenegativebreastcancer